skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Serdemetan (Code C77904)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Serdemetan

Definition: An orally bioavailable HDM2 antagonist with potential antineoplastic activity.Serdemetan inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. HDM2 (human homolog of double minute 2), a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.

Label: Serdemetan

NCI Thesaurus Code: C77904 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2703092  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
JNJ-26854165
JNJ 26854165
N-(2-(1H-Indol-3-yl)ethyl)-n'-(pyridin-4-yl)benzene-1,4-diamine
SERDEMETAN
Serdemetan

External Source Codes: 
CAS Registry Number 881202-45-5 (see NLM ChemIDplus info)
FDA UNII Code ID6YB4W3V8
PDQ Closed Trial Search ID 596734
PDQ Open Trial Search ID 596734 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703092

Other Properties:
     Name Value (qualifiers indented underneath)
code C77904
Contributing_Source FDA
Legacy_Concept_Name HDM2_Inhibitor_JNJ-26854165
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77904

Mainbox Bottom